EXPLORE THE SCIENCE
TL;DR: A 2026 randomized controlled study in Pakistan Journal of Pharmaceutical Sciences found that adding 20 Hz repetitive transcranial magnetic stimulation (rTMS) to risperidone was linked with lower cognitive-factor and aggression scores after 4 weeks in sc…
Read article
TL;DR: A 2026 BMC Psychiatry study found that antipsychotic dose was not associated with Montreal Cognitive Assessment (MoCA), a brief cognitive screening test, in clinically stable schizophrenia patients under 40, while higher symptom scores and longer illnes…
Read article
TL;DR: A 2026 randomized phase 2b trial in Journal of Clinical Psychopharmacology found that the PDE10A inhibitor MK-8189 did not improve Positive and Negative Syndrome Scale (PANSS) schizophrenia symptom scores more than placebo after 6 weeks, while risperido…
Read article
TL;DR: A 2026 randomized study in Psychological Medicine found that right orbitofrontal cortex repetitive transcranial magnetic stimulation (rTMS), a noninvasive brain-stimulation method, improved visuospatial memory on the Brief Visuospatial Memory Test-Revis…
Read article
TL;DR: A 2026 post-hoc analysis in International Clinical Psychopharmacology found that lurasidone 40 mg/day improved all 5 Positive and Negative Syndrome Scale (PANSS) symptom domains in acute schizophrenia over 6 weeks, with the largest effect on positive sy…
Read article
TL;DR: A 2026 network analysis study in European Archives of Psychiatry and Clinical Neuroscience found that insomnia was present in 18.3% and childhood trauma in 49.5% of patients, while daytime dysfunction and sleep-related distress were central nodes, while…
Read article
The study found that higher levels of brain-derived neurotrophic factor (BDNF) and better cognitive function reduce suicidal thoughts in first-episode schizophrenia patients, while more severe symptoms and higher total cholesterol levels increase the risk. Hig…
Read article